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■ Resumen
Antecedentes: Los fármacos vasoconstrictores reducen la producción de óxido nítrico (NO) in vitro inhibiendo la enzima implicada en la 
regulación de las sintetasas inducible y constitutiva (iNOS y cNOS) del óxido nítrico. Los vasoconstrictores intranasales también disminuyen 
la concentración de NO nasal in vivo. Hasta el momento se desconoce si este último hallazgo es debido a un efecto del fármaco sobre la 
enzima o sobre los vasos sanguíneos. El ejercicio físico también induce la vasoconstricción nasal y reduce resistencia nasal. 
Objetivos: El objetivo de este estudio fue intentar clarifi car los mecanismos implicados en la reducción de la concentración de nasal NO 
inducida por xilometazolina. 
Métodos: Diseñamos un estudio comparativo de dos grupos paralelos de pacientes con rinitis alérgica persistente moderada/grave. El 
primer grupo (n=24) fue sometido a un estímulo vasoconstrictor nasal fi siológico (ejercicio) mientras que el segundo grupo (n=29) fue 
tratado con un vasoconstrictor nasal (xilometazolina tópica). El volumen y el NO nasales fueron determinados de forma basal y entre 15 
a 20 minutos después de cada estímulo usando rinometría acústica y quimioluminiscencia respectivamente.
Resultados: Los valores basales del volumen y del NO nasales fueron similares en ambos grupos. El volumen nasal aumentó un 57% 
(P=0,0001) después de ejercicio y un 71% (P=0,0001) tras la aplicación de xilometazolina. El NO nasal disminuyó un 25% (P=0,001) 
con respecto a su valor basal después de la xilometazolina, pero no tras el ejercicio. 
Conclusión: Tanto el ejercicio como la xilometazolina tópica ocasionan vasoconstricción y efectos similares sobre volumen nasal. Sin 
embargo, el NO nasal se redujo con la xilometazolina pero no tras el ejercicio. Estos resultados sugieren que los fármacos vasoconstrictores 
reducen el NO nasal por mecanismos diferentes a la vasoconstricción. 
Palabras clave: Ejercicio. Óxido Nítrico Nasal. Volumen Nasal. Rinitis. Vasoconstrictores Tópicos Nasales.
■ Abstract
Background: Vasoconstrictor drugs reduce nitric oxide (NO) production in vitro by inhibiting the enzyme involved in the regulation of 
inducible and constitutive NO synthases (iNOS and cNOS). Intranasal vasoconstrictors also decrease nasal NO concentration in vivo. It 
is as yet unclear if this last fi nding is due to the effects of the drug on the enzyme or on the vessels. Physical exercise also induces nasal 
vasoconstriction and reduces nasal resistance. 
Objectives: The aim of this study was to clarify the mechanisms involved in xylometazoline-induced reduction of nasal NO concentration. 
Methods: We compared 2 randomized groups of patients with moderate–severe persistent allergic rhinitis. The fi rst group (n=24) underwent 
a physiological nasal vasoconstrictor stimulus (exercise) whereas the second group (n=29) was treated with a nasal vasoconstrictor drug 
(topical xylometazoline). Nasal volume and NO were determined at baseline and 15 to 20 minutes after the end of each stimulus using 
acoustic rhinometry and chemiluminescence, respectively.
Results: Baseline values of nasal volume and NO did not differ between the 2 groups. Nasal volume increased by 57% (P = .0001) after 
exercise and 71% (P = .0001) after xylometazoline. Nasal NO decreased (25%, P = .001) after xylometazoline, but not after exercise. 
Conclusion: Physical exercise and topical xylometazoline cause vasoconstriction and similar effects on nasal volume. In contrast nasal NO 
decreased with xylometazoline but not after exercise. These fi ndings suggest that vasoconstrictor drugs reduce nasal NO by mechanisms 
other than vasoconstriction. 
Key words: Exercise. Nasal nitric oxide. Nasal volume. Rhinitis. Topical nasal vasoconstrictors.
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Introduction
Nitric oxide (NO) is a mediator of various biological 
processes such as vasodilation and cellular immune responses. 
Through these actions NO can contribute to regulate infl ammatory 
responses in the upper airways. NO and its metabolites are found 
in high concentrations in the nose of both healthy subjects and 
patients with rhinitis [1-3]. This is attributed to the high levels 
of production of NO in the paranasal cavities, from which it 
fl ows towards the nasal cavity. The synthesis of NO is regulated 
by the action of the NO synthase (NOS) enzyme on the amino 
acid L-arginine. There are 3 isoforms of NOS. Two endothelial 
and neuronal forms, termed constitutive (cNOS), synthesize 
NO in normal conditions. The third, termed inducible (iNOS), 
is not expressed (or very weakly so) in normal conditions 
[2,3]. iNOS is present in the epithelium of the respiratory 
airway and in various infl ammatory cell types (macrophages, 
neutrophils, mastocells, endothelial cells) and can be induced 
by various proinfl ammatory cytokines (tumor necrosis factor 
α and β, interferon γ, interleukin-1β) [3]. On the basis of these 
observations iNOS has been linked to the regulation of the 
immune infl ammatory response in the airways [2,3]. iNOS 
induction requires gene transcription activation, thus, any 
increase in NO production usually occurs several hours after 
gene induction and may last for several days [4]. All in all, 
these fi ndings have led to the consideration that NO can be 
used as an indicator of infl ammation [2].
Nasal vasoconstrictors are sympathetic mimetic amines 
that activate the α-adrenergic receptors located in vascular 
smooth muscle. These drugs effectively and quickly relieve 
nasal obstruction but are less effi cacious over other rhinitis 
symptoms such as sneezing, pruritus and rhinorrhea according 
to Westerveld et al [1], who cite recent studies suggesting that 
vasoconstrictors exert part of their benefi cial pharmacological 
effects by mechanisms other than vasoconstriction. They note 
that oxymetazoline and xylometazoline inhibit cNOS and 
iNOs activity in rat macrophages in vitro in a dose-dependent 
manner, and that this effect results from reducted induction of 
the enzyme rather than a direct effect on the enzyme activity. 
A decrease in nasal NO after intranasal administration of 
vasoconstrictors has been previously reported, and although 
the mechanisms involved in this effect are still unclear, it has 
been suggested that the constriction of venous sinusoids results 
in a reduction in blood fl ow which in turn reduces the diffusion 
of NO from the tissues to the nasal cavity [5,6]. Another 
hypothesis the authors have put forward is that the reduction 
of blood fl ow could prevent the metabolite substrates from 
reaching the cells where NO is produced. A toxic effect of the 
drugs has also been suggested as a potential explanation. 
Physical exercise is also associated with an increase of nasal 
volume that in turn reduces nasal resistance in both healthy 
subjects and patients with rhinitis, and it has been shown 
that these changes are largely caused by a vasoconstrictive 
phenomenon (increase in sympathetic activity) that reduces 
the volume of the venous sinusoids [7,8]. 
Acoustic rhinometry is a technique used to assess the 
geometry of nasal cavities, including both the size of the cross-
sectional areas as well as the volume of the nasal cavities at 
various distances from the nostrils [9].
The aim of this study was to gain insight into the mechanisms 
responsible for the effect of administering a vasoconstrictor 
drug on nasal NO. Because the reduction of nasal blood fl ow 
has been proposed as one of the possible mechanisms to 
explain fi ndings of reduced nasal NO, we compared the effects 
of the drug with those of physical exercise, which is a well-
known method of inducing vasoconstriction by the release of 
endogenous sympathetic hormones. 
Patients and Methods
Patients and Design of Study
A cohort of patients with persistent severe–moderate allergic 
rhinitis according to classifi cations in the guidelines of the 
Allergic Rhinitis and Its Impact on Asthma group [10] was 
recruited. We designed a prospective study using 2 parallel 
groups. Subjects were randomized to receive 2 puffs of 
xylometazoline 1% in each nostril or to perform an exercise 
challenge for 6 minutes on a bicycle ergometer to reach 80% of 
maximal heart rate (Cardio O
2
 MGC, St Paul, Minnesota, USA) 
according to methods previously described [11]. The selected 
patients had not received any treatment with topical or systemic 
corticosteroids in the last 4 weeks or with antihistamines in 
the last week.
The study was approved by the ethics committee of 
our hospital and all patients gave their informed consent to 
participation. 
 
Nasal Volume 
Nasal volume was measure by acoustic rhinometry 
(acoustic rhinometer SER 2000 RhinoMetrics, Lynge, 
Denmark) at baseline and at 15 minutes after the end of either 
the exercise test or the intranasal instillation of xylometazoline. 
Because the main changes in nasal geometry occur in the 
most vascularized segment, which are the turbinates, the 
nasal volume was evaluated between the second and sixth 
centimeters (Vol
2–6
) of the nasal cavity using a standardized 
method [9]. 
Nasal NO
Nasal NO was measured after acoustic rhinometry 
at similar time points. Measurement was performed by 
chemiluminescence (SIR System N6008 NO tracer, SIR, 
Madrid, Spain), following a standardized method [12]. 
The system uses the light generated by a reaction between 
environmental ozone and the NO from the sample. The light is 
then amplifi ed and analyzed by specifi c software. To evaluate 
the nasal NO, the nasal air sample was obtained from one 
nostril using a negative pressure pump with a fl ow rate of 
0.05 L/s. The patients were instructed to blow out their cheeks 
to elevate the mouth pressure in order to lift up the palate 
and isolate the nasal cavity from the rest of the respiratory 
system. Measurement was made when the level reached a 
plateau value.
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Figure 1. Nasal dilation after exercise and xylometazoline. Ppb indicates 
parts per billion; NS, not signifi cant. *P < .0001.
Characteristics of Patients at Baseline*
 Exercise  Xylometazoline 
 Group Group
Gender, male/female 12/12 10/19
 
Age, mean, y 27 ± 6.7 29 ± 7.8
   
Nasal volume 
(Vol 
2-6
), cm3 14.1 ± 3.0 13.2 ± 7.4
Nasal nitric 
oxide, ppb 1165 ± 439 1287 ± 432
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Statistical Analysis
Age and values of Vol 
2–6
 and nasal NO at baseline and at 
15 minutes are presented as means ± SD. Differences within 
groups and between groups were estimated using Wilcoxon 
and Mann–Whitney analysis, respectively. The software used 
was SPSS Version 14.0 (Chicago, Illinois, USA).
Results
Fifty-three patients were studied; 29 received xylometazoline 
and 24 performed the exercise test. Demographic characteristics 
and baseline acoustic rhinometry and nasal NO values were 
similar in both groups (table). All patients were sensitized to 
house dust mites. 
At 15 minutes, the Vol
2–6
 increased by 57% ± 29% 
over baseline in the exercise group (P < .0001). In the 
xylometazoline group, the Vol
 2–6
 increased by 71% ± 32% 
over baseline at 15 minutes (P < .0001). The difference in the 
magnitude of change in Vol
2–6
 between the 2 groups was not 
statistically signifi cant (Figure 1).
Nasal NO did not change signifi cantly in the exercise 
group from the mean value at baseline of 1165 ± 439 parts 
per billion (ppb) to the mean value of 1185 ± 413 ppb at 15 
minutes after the end of exercise (P = .4). In contrast, in the 
xylometazoline group, the mean value at baseline of 1287 ± 
432 ppb decreased signifi cantly to 969 ± 337 ppb at 15 minutes 
after the intranasal administration of the drug (P < .05). The 
nasal NO concentration at 15 minutes was signifi cantly lower 
in the xylometazoline group with respect to the exercise group 
(P = .046) (Figure 2). 
Discussion
Vasodilator agents such as papaverine are associated with 
increases in nasal NO whereas vasoconstrictor drugs cause 
the opposite effect [13]. These fi ndings suggest that nasal 
blood fl ow is the mechanism involved in the regulation of 
nasal NO output.
Our study shows that both exercise and vasoconstrictor 
drugs (xylometazoline) caused a similar increase in the size 
of nasal cavities. In both cases, the mechanism involved 
in this action appears to be the reduction in the volume of 
venous sinusoids resulting from the vasoconstrictor effect 
of sympathetic substances. In one case the substance was 
exogenous and artifi cially administered intranasally and in the 
other case the sympathetic substances were supposedly produced 
by the suprarenal glands upon the physiologicall stimulation of 
physical exercise and released in the nose. However, even though 
the effect on vessels was similar, the nasal NO concentration 
signifi cantly decreased after xylometazoline instillation but not 
after exercise. This observation suggests that vasoconstriction 
per se is not the mechanism responsible for the xylometazoline-
induced nasal NO reduction. Westerveld et al [1], reported 
that vasoconstrictor drugs reduce the inducible form of NO 
synthase activity in vitro. Whether xylometazoline reduces 
*Vol2-6 indicates the volume evaluated between the second and sixth 
centimeters. Data are means ± SD.
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m
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Figure 2. Nasal nitric oxide at baseline and 15 minutes after stimuli. The 
value is expressed in parts per billion (ppb). *P < .05. 
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nasal NO in vivo in the nose by a direct effect on the enzymes 
involved in the production of NO is a possibility that remains 
to be demonstrated. 
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